STA
SUPN icon

Summit Trail Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Summit Trail Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-42,353
Closed -$1.62M – 659
2018
Q1 		$1.62M Buy
42,353
+4,245
+11% +$177K 0.27% 76
2017
Q4 		$1.63M Buy
+38,108
New +$1.51M 0.21% 93

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Summit Trail Advisors's SUPN Position: Q2 2018 in Review

Summit Trail Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2018, closing a stake of 42,353 shares — an estimated $1.62M sold.

Summit Trail Advisors first reported a position in SUPN in Q4 2017 and held it in 2 quarters. The position peaked at $1.63M in Q4 2017. 320 funds tracked by Wall St. Rank hold SUPN as of Q2 2018.

  • Summit Trail Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 42,353 Supernus Pharmaceuticals shares in Q2 2018, an estimated $1.62M.
  • Summit Trail Advisors first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Summit Trail Advisors's Supernus Pharmaceuticals position peaked at $1.63M in Q4 2017.
  • 320 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2018.

Based on Summit Trail Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.